

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02 Issue Date: 10/08/15 Rev. No: 07 LAB 029</b>
---	-----------------------------------	---

## **Accreditation No: LAB 029**

### **Awarded to**

Shaigan Pharmaceuticals Research and Testing Laboratories.  
Rawalpindi City, Pakistan.

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **19-03-2009** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **30-08-2021**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

**15-04-2020**

Date

\_\_\_\_\_  
Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 029</b>
---	-----------------------------------	---

## Testing Laboratory.

Accreditation Scope of Shaigan Pharmaceuticals Research and Testing Laboratories. Rawalpindi City, Pakistan.

Permanent laboratory premises

S. No.	Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
1	Bexus 250 Tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.2 ; Page 2555 -2557
			Uniformity of weight	BP 2020 Appendix XII C V-A408 - V-A409
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
2	Bexus 500 Tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.2 ; Page 2555 -2557
			Uniformity of weight	BP 2020 Appendix XII C V-A408 - V-A409
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
3	Bexus 750 Tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.2 ; Page 2555 -2557
			Uniformity of weight	BP 2020 Appendix XII C V-A408 - V-A409
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
4	Bexus 250 Infusion	Pharmaceutical Testing	Quantitative Analysis	JP XVII Vol. 2; Page 1156 - 1157
			pH	In-house (QC-BXS2-INF)
5	Bexus 500 Infusion	Pharmaceutical Testing	Quantitative Analysis	JP XVII Vol. 2; Page 1156 - 1157
			pH	In-house (QC-BXS5-INF)
6	Bexus 750 Infusion	Pharmaceutical Testing	Quantitative Analysis	JP XVII Vol. 2; Page 1156 - 1157
			pH	In-house (QC-BXS7-INF)
7	Clozox T- Cream	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.1 ; Page 1097 -1098
			pH	In-house (QC-CLT-CRM)
8	Clozox 0.1g Tablets	Pharmaceutical Testing	Quantitative Analysis	In-house (QC-CV1-TAB)
			Friability	BP 2020 Appendix XVII G V-A572 - V-A573
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387

**15-04-2020**

Date

\_\_\_\_\_  
Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 029</b>
---	-----------------------------------	---

9	Clozox 0.5g Tablets	Pharmaceutical Testing	Quantitative Analysis	In-house (QC-CV5-TAB)
			Friability	BP 2020 Appendix XVII G V-A572 - V-A573
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
10	Clozox V- Cream	Pharmaceutical Testing	Quantitative Analysis	In-house (QC-CVC-CRM)
			pH	
11	Clycin V Cream	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.1 ; Page 1050 - 1051
			pH	USP 2019 Vol.1 ; Page 1050 - 1051
12	Clycin T Lotion	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.1 ; Page 1052
			pH	USP 2019 Vol.1 ; Page 1052
13	Famot 20 Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 609 -610
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
14	Famot 40 Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 609 - 610
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
15	Fudic Cream	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 677 678
			pH	
16	Warfin 1mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 1429 - 1430
			Friability	BP 2020 Appendix XVII G V-A572 - V-A573
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
17	Warfin 2.5mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 1429 - 1430
			Friability	BP 2020 Appendix XVII G V-A572 - V-A573
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
18	Warfin 5.0mg Tablets	Pharmaceutical Testing	Quantitative Analysis	BP 2020 Vol. III ; Page 1429 1430
			Friability	BP 2020 Appendix XVII G V-A572 - V-A573
			Disintegration test	BP 2020 Appendix XII A V-A384 - V-A387
19	Esso 40 capsules	Pharmaceutical Testing	Assay	USP 2019 Vol.1 ; Page 1680 - 1684
20	Esso 20 capsules	Pharmaceutical Testing	Assay	USP 2019 Vol.1 ; Page 1680 - 1684

**15-04-2020**

Date

Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 029</b>
---	-----------------------------------	---

21	Peflox Tablets	Pharmaceutical Testing	Quantitative Analysis	In-house (QC-PEF-TAB)
			Uniformity of weight	BP 2020 Appendix XII C V-A408 - V-A409
			Disintegration test	BP 2020 Appendix XII A V- A384 - V-A387
22	Zepar Tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.1 ; Page 104 - 105
			Uniformity of weight	BP 2020 Appendix XII C V-A408 - V-A409
			Disintegration test	BP 2020 Appendix XII A V- A384 - V-A387
23	ZeparSuspension	Pharmaceutical Testing	Quantitative Analysis pH	In-house (QC-ZPR-SUS)
24	Ergomin tablets	Pharmaceutical Testing	Quantitative Analysis	USP 2019 Vol.II ; Page 2848 - 2849
25	Esso 40 I.V	Pharmaceutical Testing	Quantitative Analysis	In-house (QC-ES4-INJ)
			pH	
26	Water For Injection	Pharmaceutical Testing	pH	BP 2020 Vol. II ; Page 1288 - 1291
			Conductivity	USP 2019 Vol.II ; Page 4610 - 4611
27	Albendazole	Pharmaceutical Testing	Quantitative analysis	USP 2019 Vol.1 ; Page 103 - 104
			Identification by FTIR	
28	Clindamycin Phosphate	Pharmaceutical Testing	Quantitative analysis	USP 2019 Vol.I ; Page 1049 - 1050
		Pharmaceutical Testing	Identification by FTIR	
		Pharmaceutical Testing	pH Water content	
29	Clotrimazole	Pharmaceutical Testing	Quantitative analysis	USP 2019 Vol.I ; Page 1096 - 1097
			Identification by FTIR	
30	Famotidine	Pharmaceutical Testing	Quantitative analysis	BP 2020 Vol. I ; Page 1012 1013
			Identification	
31	Pefloxacin Mesilate	Pharmaceutical Testing	Quantitative analysis	In-house (QC-TP-RMA-077)  BP 2020 Vol. II ; Page 546 - 548
			Identification by FTIR	
			pH	
			Water content	
32	Warfarin Sodium Clathrate.	Pharmaceutical Testing	Quantitative analysis	BP 2020 Vol. II ; Page 1285 - 1286
			Identification by FTIR	
			pH	
			Water content	
33	Esomeprazole	Pharmaceutical Testing	Assay	USP 2019 Vol.1 ; Page 1680 - 1684
			Water Content	In-house (QC-TP-RMA-029)
34	Methyl Ergometrine Maleate	Pharmaceutical Testing	Assay	USP 2019 Vol.II ; Page 2846 - 2847
			Identification by FTIR	
			pH	

**15-04-2020**

Date

Director

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 029</b>
---	-----------------------------------	---

<b>35</b>	<b>Levofloxacin hemi hydrate</b>	Pharmaceutical Testing	Quantitative analysis	USP 2019 Vol.II ; Page 2552 - 2554
			Identification by FTIR	
			Water content	
<b>36</b>	<b>Fusidic Acid</b>	Pharmaceutical Testing	Quantitative analysis	BP 2020 Vol. I ; Page 1139 - 1141
			Identification by FTIR	
			Water content	

**15-04-2020**  
Date

\_\_\_\_\_  
Director